Profile | GDS2987 / GI_32699006-I |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 11.5 | 38 |
GSM215244 | HMVEC_vehicle_rep2 | 5.5 | 14 |
GSM215253 | HMVEC_vehicle_rep3 | 9.8 | 32 |
GSM215254 | HMVEC_atorvastatin_rep1 | 4.7 | 13 |
GSM215282 | HMVEC_atorvastatin_rep3 | 2.4 | 6 |
GSM215344 | HMVEC_atorvastatin_rep2 | 24.1 | 50 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 8.6 | 17 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 22.3 | 41 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 40.6 | 55 |
GSM215294 | HMVEC_SLx2119_rep1 | 8.8 | 31 |
GSM215295 | HMVEC_SLx2119_rep2 | 15.7 | 31 |
GSM215296 | HMVEC_SLx2119_rep3 | 18.1 | 30 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 1.3 | 2 |
GSM215311 | PASMC_atorvastatin_rep1 | 33.2 | 50 |
GSM215312 | PASMC_atorvastatin_rep2 | 14 | 23 |
GSM215313 | PASMC_atorvastatin_rep3 | 39.6 | 51 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 24.8 | 43 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 10.9 | 19 |
GSM215327 | PASMC_SLx2119_rep1 | 11.1 | 20 |
GSM215328 | PASMC_SLx2119_rep2 | 17.3 | 31 |
GSM215329 | PASMC_SLx2119_rep3 | 18.1 | 34 |
GSM215330 | Fibroblasts_vehicle_rep1 | 10.6 | 25 |
GSM215331 | Fibroblasts_vehicle_rep2 | 8.8 | 25 |
GSM215332 | Fibroblasts_vehicle_rep3 | 8.4 | 28 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 4.9 | 13 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 3.4 | 10 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 9.5 | 24 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 9.1 | 30 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 2.7 | 9 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 13 | 35 |
GSM215339 | Fibroblasts_SLx2119_rep1 | ||
GSM215340 | Fibroblasts_SLx2119_rep2 | 7.6 | 21 |
GSM215341 | Fibroblasts_SLx2119_rep3 |